Abstract
In nine chronic haemodialysis patients a desferrioxamine (DFO) load test (40 mg/kg body-weight) was performed 1 year after the beginning of treatment with recombinant human erythropoietin (rHuEpo). The patients were then divided into two groups. Group A comprised five patients with a greater mean aluminium (204 ± 28 μg/l) than the four patients in group B. Group A was given a mean dose of 25.8 g (range 14-39 g) of DFO over 6 months. Group B (aluminium values 112 ± 36 μg/l) was never treated with DFO. During the period of observation, plasma iron, serum ferritin and transferrin, as well as iron supplementation, did not differ between the groups. After DFO treatment a second DFO load test was performed. The mean predialysis aluminium value was significantly reduced in group A (204 ± 28 vs 111 ± 72 μg/l; P <0.05), while remaining unchanged in group B (112 ± 36 vs 140 ± 39 μg/l; P = ns). In both groups, the doses of rHuEpo necessary to maintain the same haemoglobin values decreased with time, but reduced significantly only in group A (298 ± 105 vs 110 ± 61 μg/kg per week; Δ -63%; P <0.01). Thus, aluminium interferes with the response to rHuEpo in haemodialysis patients, and the correction of aluminium overload with DFO can allow a considerable sparing of rHuEpo.
| Original language | English |
|---|---|
| Pages (from-to) | 441-443 |
| Number of pages | 3 |
| Journal | Nephrology Dialysis Transplantation |
| Volume | 5 |
| Issue number | 6 |
| Publication status | Published - 1990 |
Fingerprint
Keywords
- aluminium
- anaemia
- desferrioxamine
- haemodialysis
- recombinant human erythropoietin, rHuEpo
ASJC Scopus subject areas
- Nephrology
- Transplantation
Cite this
Aluminium interference in the treatment of haemodialysis patients with recombinant human erythropoietin. / Casati, S.; Castelnovo, C.; Campise, M.; Ponticelli, C.
In: Nephrology Dialysis Transplantation, Vol. 5, No. 6, 1990, p. 441-443.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Aluminium interference in the treatment of haemodialysis patients with recombinant human erythropoietin
AU - Casati, S.
AU - Castelnovo, C.
AU - Campise, M.
AU - Ponticelli, C.
PY - 1990
Y1 - 1990
N2 - In nine chronic haemodialysis patients a desferrioxamine (DFO) load test (40 mg/kg body-weight) was performed 1 year after the beginning of treatment with recombinant human erythropoietin (rHuEpo). The patients were then divided into two groups. Group A comprised five patients with a greater mean aluminium (204 ± 28 μg/l) than the four patients in group B. Group A was given a mean dose of 25.8 g (range 14-39 g) of DFO over 6 months. Group B (aluminium values 112 ± 36 μg/l) was never treated with DFO. During the period of observation, plasma iron, serum ferritin and transferrin, as well as iron supplementation, did not differ between the groups. After DFO treatment a second DFO load test was performed. The mean predialysis aluminium value was significantly reduced in group A (204 ± 28 vs 111 ± 72 μg/l; P <0.05), while remaining unchanged in group B (112 ± 36 vs 140 ± 39 μg/l; P = ns). In both groups, the doses of rHuEpo necessary to maintain the same haemoglobin values decreased with time, but reduced significantly only in group A (298 ± 105 vs 110 ± 61 μg/kg per week; Δ -63%; P <0.01). Thus, aluminium interferes with the response to rHuEpo in haemodialysis patients, and the correction of aluminium overload with DFO can allow a considerable sparing of rHuEpo.
AB - In nine chronic haemodialysis patients a desferrioxamine (DFO) load test (40 mg/kg body-weight) was performed 1 year after the beginning of treatment with recombinant human erythropoietin (rHuEpo). The patients were then divided into two groups. Group A comprised five patients with a greater mean aluminium (204 ± 28 μg/l) than the four patients in group B. Group A was given a mean dose of 25.8 g (range 14-39 g) of DFO over 6 months. Group B (aluminium values 112 ± 36 μg/l) was never treated with DFO. During the period of observation, plasma iron, serum ferritin and transferrin, as well as iron supplementation, did not differ between the groups. After DFO treatment a second DFO load test was performed. The mean predialysis aluminium value was significantly reduced in group A (204 ± 28 vs 111 ± 72 μg/l; P <0.05), while remaining unchanged in group B (112 ± 36 vs 140 ± 39 μg/l; P = ns). In both groups, the doses of rHuEpo necessary to maintain the same haemoglobin values decreased with time, but reduced significantly only in group A (298 ± 105 vs 110 ± 61 μg/kg per week; Δ -63%; P <0.01). Thus, aluminium interferes with the response to rHuEpo in haemodialysis patients, and the correction of aluminium overload with DFO can allow a considerable sparing of rHuEpo.
KW - aluminium
KW - anaemia
KW - desferrioxamine
KW - haemodialysis
KW - recombinant human erythropoietin, rHuEpo
UR - http://www.scopus.com/inward/record.url?scp=0025354482&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025354482&partnerID=8YFLogxK
M3 - Article
C2 - 2122321
AN - SCOPUS:0025354482
VL - 5
SP - 441
EP - 443
JO - Nephrology Dialysis Transplantation
JF - Nephrology Dialysis Transplantation
SN - 0931-0509
IS - 6
ER -